Inventor
NORBERT SCHMEES
Inventor
DE
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds31%
C07BGeneral methods of organic chemistry4%
C07KPeptides4%
PatentTitleYear
12,522,5942-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer202612,478,621Substituted aminoquinolones as dgkalpha inhibitors for immune activation202511,998,539Substituted aminoquinolones as DGKalpha inhibitors for immune activation202411,964,953Substituted aminothiazoles as DGKzeta inhibitors for immune activation202411,795,1642-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer202311,524,9442-phenylpyrimidine-4-carboxamides as AHR inhibitors202211,304,9462-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists202211,161,8254-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2025Patents assigned to BAYER AG (7)· patent assignee history
2021–2025Patents assigned to Bayer Pharma AG (6)· patent assignee history
2021–2026Based in DE· patent location history
2022–2026Patents assigned to DEUTSCHES KREBSFORSCH (7)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BAYER AG | 7 | 2021–2025 |
| DEUTSCHES KREBSFORSCH | 7 | 2022–2026 |
| Bayer Pharma AG | 6 | 2021–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| DE | 8 | 2021–2026 |